Lisata Therapeutics, Inc. – NASDAQ:LSTA
Lisata Therapeutics stock price today
Lisata Therapeutics stock price monthly change
Lisata Therapeutics stock price quarterly change
Lisata Therapeutics stock price yearly change
Lisata Therapeutics key metrics
Market Cap | 23.16M |
Enterprise value | N/A |
P/E | -0.3 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.24 |
PEG ratio | N/A |
EPS | -2.46 |
Revenue | N/A |
EBITDA | -26.66M |
Income | -20.05M |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLisata Therapeutics stock price history
Lisata Therapeutics stock forecast
Lisata Therapeutics financial statements
| Jun 2023 | 0 | -4.02M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.26M | |
| Dec 2023 | 0 | -5.36M | |
| Mar 2024 | 0 | -5.40M |
| 2025 | 0 | -30.02M | |
|---|---|---|---|
| 2026 | 0 | -28.3M | |
| 2027 | 0 | -14.45M | |
| 2028 | 7.2M | -13.48M | -187.25% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 62365000 | 4.65M | 7.46% |
|---|---|---|---|
| Sep 2023 | 58089000 | 5.38M | 9.27% |
| Dec 2023 | 54694000 | 6.8M | 12.43% |
| Mar 2024 | 48240000 | 5.49M | 11.4% |
| Jun 2023 | -4.18M | -725K | 452K |
|---|---|---|---|
| Sep 2023 | -3.58M | 12.25M | -6K |
| Dec 2023 | -4.06M | -5.71M | 24K |
| Mar 2024 | -7.02M | 6.43M | -142K |
Lisata Therapeutics alternative data
| Aug 2023 | 27 |
|---|---|
| Sep 2023 | 27 |
| Oct 2023 | 27 |
| Nov 2023 | 27 |
| Dec 2023 | 27 |
| Jan 2024 | 27 |
| Feb 2024 | 27 |
| Mar 2024 | 25 |
| Apr 2024 | 25 |
| May 2024 | 25 |
| Jun 2024 | 25 |
| Jul 2024 | 25 |
Lisata Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 33785 | 0 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 4 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 17 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Lisata Therapeutics stock today?
One share of Lisata Therapeutics stock can currently be purchased for approximately $2.49.
-
When is Lisata Therapeutics's next earnings date?
Unfortunately, Lisata Therapeutics's (LSTA) next earnings date is currently unknown.
-
Does Lisata Therapeutics pay dividends?
No, Lisata Therapeutics does not pay dividends.
-
How much money does Lisata Therapeutics make?
Lisata Therapeutics has a market capitalization of 23.16M.
-
What is Lisata Therapeutics's stock symbol?
Lisata Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "LSTA".
-
What is Lisata Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Lisata Therapeutics?
Shares of Lisata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Lisata Therapeutics have?
As Jul 2024, Lisata Therapeutics employs 25 workers.
-
When Lisata Therapeutics went public?
Lisata Therapeutics, Inc. is publicly traded company for more then 26 years since IPO on 1 Mar 1999.
-
What is Lisata Therapeutics's official website?
The official website for Lisata Therapeutics is lisata.com.
-
Where are Lisata Therapeutics's headquarters?
Lisata Therapeutics is headquartered at 110 Allen Road, Basking Ridge, NJ.
-
How can i contact Lisata Therapeutics?
Lisata Therapeutics's mailing address is 110 Allen Road, Basking Ridge, NJ and company can be reached via phone at +90 88420100.
Lisata Therapeutics company profile:
Lisata Therapeutics, Inc.
lisata.comNASDAQ
25
Biotechnology
Healthcare
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Basking Ridge, NJ 07920
CIK: 0000320017
ISIN: US1280583022
CUSIP: 128058302
